RedHill Biopharma Ltd. announced the appointment of Dr. Shmuel Cabilly, PhD, to its Board of Directors until the Company's next annual general meeting, effective September 22, 2019. Dr. Cabilly previously served as a member of RedHill's Board of Directors from August 26, 2010 until the end of his term on June 24, 2019. Dr. Cabilly also served on RedHill's compensation committee from May 5, 2011 until June 24, 2019. Dr. Cabilly is a scientist and inventor in the field of immunology. In the Backman Research Institute of the City of Hope, Dr. Cabilly initiated the development of a new breakthrough technology for recombinant antibody production, which was patented and known as the "Cabilly Patent".